Thanks. You're the best. I forgot about the who
Post# of 154604
(Total Views: 415)
Posted On: 05/07/2025 10:35:48 AM
Thanks. You're the best.
I forgot about the whole drama with Patterson trying to take things over and his fallout with Cytodyn, so they went with Jonah Sacha and colleagues for the RO publication.
Great to see that work in monkeys and the CoV trial data. Hopefully full RO via their assays correlates with HIV protection (though I guess somehow our data was not good enough in regular HIV treatment and we will now be going after inflammation in HIV, pre-exposure prophylaxis - a tough one, as there are already long acting PEP drugs on the market, and last of all HIV cure with concomitant HSPC transplants!) and also with blockage of chemokine signalling via CCR5 (for our cancer and numerous anti-inflammatory indications).
Definitely feel more confident that we can block chemokines from binding to CCR5 with the 700 mg dosages, with weekly dosing. It will be interesting to see what Sacha comes up with for the "LL gene therapy" to constantly produce LL and block CCR5, or for our other efforts to extend the half-life of LL. (There were clinical trial efforts by SGMO to edit HSPCs so that all T-cells would have CCR5 knocked out, and of course the Chinese guy who gene edited out CCR5 in embryos via CRISPR. Finally, INO has a technology to produce antibodies after IM/SC DNA injection with a little zap to open the cells in vivo.)
Hopefully we will be making some traction with LL in cancer in the near future. Looking forward to long term survival data coming out at ESMO.
I forgot about the whole drama with Patterson trying to take things over and his fallout with Cytodyn, so they went with Jonah Sacha and colleagues for the RO publication.
Great to see that work in monkeys and the CoV trial data. Hopefully full RO via their assays correlates with HIV protection (though I guess somehow our data was not good enough in regular HIV treatment and we will now be going after inflammation in HIV, pre-exposure prophylaxis - a tough one, as there are already long acting PEP drugs on the market, and last of all HIV cure with concomitant HSPC transplants!) and also with blockage of chemokine signalling via CCR5 (for our cancer and numerous anti-inflammatory indications).
Definitely feel more confident that we can block chemokines from binding to CCR5 with the 700 mg dosages, with weekly dosing. It will be interesting to see what Sacha comes up with for the "LL gene therapy" to constantly produce LL and block CCR5, or for our other efforts to extend the half-life of LL. (There were clinical trial efforts by SGMO to edit HSPCs so that all T-cells would have CCR5 knocked out, and of course the Chinese guy who gene edited out CCR5 in embryos via CRISPR. Finally, INO has a technology to produce antibodies after IM/SC DNA injection with a little zap to open the cells in vivo.)
Hopefully we will be making some traction with LL in cancer in the near future. Looking forward to long term survival data coming out at ESMO.
(11)
(0)